Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Tax Provisions: 2010-2025

Historic Tax Provisions for Ironwood Pharmaceuticals (IRWD) over the last 5 years, with Sep 2025 value amounting to $27.9 million.

  • Ironwood Pharmaceuticals' Tax Provisions rose 103.60% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 12.97%. This contributed to the annual value of $64.3 million for FY2024, which is 22.97% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Tax Provisions stood at $27.9 million for Q3 2025, which was up 96.44% from $14.2 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Tax Provisions' 5-year high stood at $32.1 million during Q4 2023, with a 5-year trough of -$336.9 million in Q2 2021.
  • For the 3-year period, Ironwood Pharmaceuticals' Tax Provisions averaged around $17.4 million, with its median value being $18.0 million (2023).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Tax Provisions skyrocketed by 3,997.22% in 2022, and later tumbled by 87.79% in 2025.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Tax Provisions stood at $4.9 million in 2021, then soared by 377.55% to $23.4 million in 2022, then skyrocketed by 37.18% to $32.1 million in 2023, then crashed by 32.34% to $21.7 million in 2024, then soared by 103.60% to $27.9 million in 2025.
  • Its last three reported values are $27.9 million in Q3 2025, $14.2 million for Q2 2025, and $1.1 million during Q1 2025.